A comparison of epithelial membrane antigen overexpression in benign malignant endometrium

Pluvio J. Coronado, Maria Fasero, Jose A. Vidart, Javier Puerta, Javier Magrina, Vicente Furio-Bacete, Manuel Escudero

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective. The aim of this study was to analyze the value of epithelial membrane antigen (EMA) overexpression in benign and malignant endometrium and its prognostic significance. Methods. EMA immunostaining was performed in 178 paraffin-embedded specimens including 105 endometrial cancers, 40 endometrial hyperplasias, and 33 benign endometriums. EMA immunostaining was correlated with traditional prognostic factors and progression-free survival in endometrial cancer specimens. Results. EMA overexpression was observed more frequently in adenocarcinomas (60%) than in hyperplasias (15%) or benign endometrium (9.1%). EMA overexpression was observed in two patients with endometrial hyperplasia who progressed to carcinoma. In adenocarcinomas, EMA overexpression had a positive correlation with nonendometrioid subtypes (P = 0.012). In multivariate analysis, FIGO stage (P = 0.025) and EMA overexpression (P = 0.017) were independent prognostic factors for progression-free survival. Conclusions. EMA overexpression appears to be a marker of malignant transformation in the endometrium and it is an independent predictor of recurrent disease in endometrial cancer.

Original languageEnglish (US)
Pages (from-to)483-488
Number of pages6
JournalGynecologic Oncology
Volume82
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Mucin-1
Endometrium
Endometrial Neoplasms
Endometrial Hyperplasia
Disease-Free Survival
Adenocarcinoma
Paraffin
Hyperplasia
Multivariate Analysis
Carcinoma

Keywords

  • Endometrial cancer
  • Epithelial membrane antigen
  • Prognostic factors
  • Recurrence
  • Survival

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Coronado, P. J., Fasero, M., Vidart, J. A., Puerta, J., Magrina, J., Furio-Bacete, V., & Escudero, M. (2001). A comparison of epithelial membrane antigen overexpression in benign malignant endometrium. Gynecologic Oncology, 82(3), 483-488. https://doi.org/10.1006/gyno.2001.6283

A comparison of epithelial membrane antigen overexpression in benign malignant endometrium. / Coronado, Pluvio J.; Fasero, Maria; Vidart, Jose A.; Puerta, Javier; Magrina, Javier; Furio-Bacete, Vicente; Escudero, Manuel.

In: Gynecologic Oncology, Vol. 82, No. 3, 2001, p. 483-488.

Research output: Contribution to journalArticle

Coronado, PJ, Fasero, M, Vidart, JA, Puerta, J, Magrina, J, Furio-Bacete, V & Escudero, M 2001, 'A comparison of epithelial membrane antigen overexpression in benign malignant endometrium', Gynecologic Oncology, vol. 82, no. 3, pp. 483-488. https://doi.org/10.1006/gyno.2001.6283
Coronado PJ, Fasero M, Vidart JA, Puerta J, Magrina J, Furio-Bacete V et al. A comparison of epithelial membrane antigen overexpression in benign malignant endometrium. Gynecologic Oncology. 2001;82(3):483-488. https://doi.org/10.1006/gyno.2001.6283
Coronado, Pluvio J. ; Fasero, Maria ; Vidart, Jose A. ; Puerta, Javier ; Magrina, Javier ; Furio-Bacete, Vicente ; Escudero, Manuel. / A comparison of epithelial membrane antigen overexpression in benign malignant endometrium. In: Gynecologic Oncology. 2001 ; Vol. 82, No. 3. pp. 483-488.
@article{60b922b1a1d94b50a0edc1133cbb39d2,
title = "A comparison of epithelial membrane antigen overexpression in benign malignant endometrium",
abstract = "Objective. The aim of this study was to analyze the value of epithelial membrane antigen (EMA) overexpression in benign and malignant endometrium and its prognostic significance. Methods. EMA immunostaining was performed in 178 paraffin-embedded specimens including 105 endometrial cancers, 40 endometrial hyperplasias, and 33 benign endometriums. EMA immunostaining was correlated with traditional prognostic factors and progression-free survival in endometrial cancer specimens. Results. EMA overexpression was observed more frequently in adenocarcinomas (60{\%}) than in hyperplasias (15{\%}) or benign endometrium (9.1{\%}). EMA overexpression was observed in two patients with endometrial hyperplasia who progressed to carcinoma. In adenocarcinomas, EMA overexpression had a positive correlation with nonendometrioid subtypes (P = 0.012). In multivariate analysis, FIGO stage (P = 0.025) and EMA overexpression (P = 0.017) were independent prognostic factors for progression-free survival. Conclusions. EMA overexpression appears to be a marker of malignant transformation in the endometrium and it is an independent predictor of recurrent disease in endometrial cancer.",
keywords = "Endometrial cancer, Epithelial membrane antigen, Prognostic factors, Recurrence, Survival",
author = "Coronado, {Pluvio J.} and Maria Fasero and Vidart, {Jose A.} and Javier Puerta and Javier Magrina and Vicente Furio-Bacete and Manuel Escudero",
year = "2001",
doi = "10.1006/gyno.2001.6283",
language = "English (US)",
volume = "82",
pages = "483--488",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A comparison of epithelial membrane antigen overexpression in benign malignant endometrium

AU - Coronado, Pluvio J.

AU - Fasero, Maria

AU - Vidart, Jose A.

AU - Puerta, Javier

AU - Magrina, Javier

AU - Furio-Bacete, Vicente

AU - Escudero, Manuel

PY - 2001

Y1 - 2001

N2 - Objective. The aim of this study was to analyze the value of epithelial membrane antigen (EMA) overexpression in benign and malignant endometrium and its prognostic significance. Methods. EMA immunostaining was performed in 178 paraffin-embedded specimens including 105 endometrial cancers, 40 endometrial hyperplasias, and 33 benign endometriums. EMA immunostaining was correlated with traditional prognostic factors and progression-free survival in endometrial cancer specimens. Results. EMA overexpression was observed more frequently in adenocarcinomas (60%) than in hyperplasias (15%) or benign endometrium (9.1%). EMA overexpression was observed in two patients with endometrial hyperplasia who progressed to carcinoma. In adenocarcinomas, EMA overexpression had a positive correlation with nonendometrioid subtypes (P = 0.012). In multivariate analysis, FIGO stage (P = 0.025) and EMA overexpression (P = 0.017) were independent prognostic factors for progression-free survival. Conclusions. EMA overexpression appears to be a marker of malignant transformation in the endometrium and it is an independent predictor of recurrent disease in endometrial cancer.

AB - Objective. The aim of this study was to analyze the value of epithelial membrane antigen (EMA) overexpression in benign and malignant endometrium and its prognostic significance. Methods. EMA immunostaining was performed in 178 paraffin-embedded specimens including 105 endometrial cancers, 40 endometrial hyperplasias, and 33 benign endometriums. EMA immunostaining was correlated with traditional prognostic factors and progression-free survival in endometrial cancer specimens. Results. EMA overexpression was observed more frequently in adenocarcinomas (60%) than in hyperplasias (15%) or benign endometrium (9.1%). EMA overexpression was observed in two patients with endometrial hyperplasia who progressed to carcinoma. In adenocarcinomas, EMA overexpression had a positive correlation with nonendometrioid subtypes (P = 0.012). In multivariate analysis, FIGO stage (P = 0.025) and EMA overexpression (P = 0.017) were independent prognostic factors for progression-free survival. Conclusions. EMA overexpression appears to be a marker of malignant transformation in the endometrium and it is an independent predictor of recurrent disease in endometrial cancer.

KW - Endometrial cancer

KW - Epithelial membrane antigen

KW - Prognostic factors

KW - Recurrence

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0034823963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034823963&partnerID=8YFLogxK

U2 - 10.1006/gyno.2001.6283

DO - 10.1006/gyno.2001.6283

M3 - Article

C2 - 11520144

AN - SCOPUS:0034823963

VL - 82

SP - 483

EP - 488

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -